What it does
The networking and cyber division offers telecoms and network solutions, focusing on advanced software and cybersecurity, to tier 1 businesses and governments worldwide.
The bio-medical division focuses on the development and provision of diagnostic lab equipment as well as products to treat biological waste products from the medical, agricultural, and pharmaceutical sectors.
The group is listed on the main board of the London Stock Exchange and is headquartered in Israel with offices in North America, Europe, and the Far East.
How is it doing
For the year ended 31 December, 2019, the networking tech and bio-medical firm reported underlying earnings (EBITDA) of US$9.8mln, up from US$4.9mln in 2018, while revenues rose to US$123.4mln from US$119.6mln. Adjusted operating profit, meanwhile, was up to US$5.3mln from US$2.6mln.
CEO Zvi Marom said revenues in the second half had been 20% higher year-on-year, which alongside a “robust fourth quarter” had helped deliver “increased sales and profit…along with strong cash generation”.
As a result of the improved performance, Marom said the company had entered 2020 with a “substantially higher” order backlog than the previous year.
The company said it expected growth in both its networking and bio-medical divisions for the coming year, and as a result, BATM expected that its 2020 performance will be “in line with market expectations”.
- In late February, the company revealed that its Bio-Medical division had successfully developed a new diagnostics kit to detect the coronavirus
- In early February, BATM secured a third international contract for its agri-waste treatment solution with a major poultry processor in the Middle East
- The company won a US$4mln cybersecurity contract from a long-standing government defence department customer in late-February